<DOC>
	<DOCNO>NCT01053325</DOCNO>
	<brief_summary>Malaria major contributor disease burden Sub-Saharan Africa : 90 % global case occur , pregnant woman child 5 year vulnerable . Malaria pregnancy increase risk abortion , stillbirth , prematurity , intrauterine growth retardation maternal anemia , associate high risk low birth weight perinatal , neonatal infant mortality . For prevention control malaria pregnancy , WHO recommend Intermittent Preventive Treatment ( IPT ) antimalarial drug , insecticide treat net ( ITNs ) effective treatment malaria anemia . HIV pregnancy increase risk malaria , seem efficacy IPT drug sulphadoxine-pyrimethamine ( SP ) decrease HIV+ pregnant woman . Malaria prevention pregnancy Zambia rely ITNs IPT SP . Daily prophylaxis cotrimoxazole ( CTX ) effectively reduce mortality morbidity HIV+ individual , antibiotic therapy pregnancy might help decrease adverse pregnancy outcome . CTX prophylaxis improve birth outcome HIV+ woman CD4 &lt; 200/µl : study conclude antenatal provision CTX beneficial HIV+ pregnant woman low CD4 woman ≥200/µl ( however , study carry area low risk malaria , CTX may different effect depend endemic condition ) . The WHO recommend daily CTX addition ARVs , prevent opportunistic infection HIV+ patient . Concurrent administration SP CTX may increase incidence severe adverse reaction HIV+ patient , WHO promote CTX prophylaxis alternative SP IPT immuno-compromised pregnant woman . Unfortunately , insufficient information effectiveness daily CTX prevent malaria infection pregnancy : , SP still antimalarial recommend WHO purpose . With increase SP resistance newer antimalarial still study safety efficacy pregnancy , CTX could alternative SP reduce malaria malaria-related morbidity mortality pregnancy . This study try see HIV- HIV+ pregnant woman , CTX inferior SP reduce placental parasitaemia . Such information need issue update , effective guideline malaria prevention pregnancy</brief_summary>
	<brief_title>Establishing Effectiveness Daily Co-trimoxazole Prophylaxis For Prevention Malaria Pregnancy</brief_title>
	<detailed_description>Malaria major contributor disease burden Sub-Saharan Africa : 90 % global case occur Sub-Saharan Africa , pregnant woman child &lt; 5 represent vulnerable population . P.falciparum infection pregnancy lead parasite sequestration maternal placental vascular space , cause increase risk abortion , stillbirth , prematurity , intrauterine growth retardation maternal anaemia ; also associate increase risk low birth weight ( LBW ) perinatal , neonatal infant mortality.In low transmission area , malaria severe high risk maternal perinatal mortality ( 60-70 % ) . In highly endemic area , malaria still associate maternal anaemia , LBW stillbirth . For prevention control malaria pregnancy , WHO recommend Intermittent Preventive Treatment ( IPT ) , insecticide treat net ( ITNs ) effective case management malaria anaemia . HIV-1 infection pregnancy increase risk malaria . In HIV+ pregnant woman , addition , efficacy IPT sulphadoxine-pyrimethamine ( SP ) appear decreased . In Zambia , malaria incidence rate increase 121.5/1000 1976 482.0/1000 2003 . The high rate predominantly evident among pregnant woman child &lt; five . Malaria prevention pregnancy Zambia rely ITNs IPT SP . Several study Zambia Uganda demonstrate daily cotrimoxazole ( CTX ) prophylaxis effective reduce mortality morbidity HIV+ individual antibiotic therapy pregnancy might impact positively reduction adverse pregnancy outcome . CTX prophylaxis significantly improve birth outcome HIV+ woman CD4 &lt; 200/µl . A recent study Zambia conclude antenatal provision CTX beneficial HIV+ pregnant woman low CD4 woman ≥200/µl . However , study carry area extremely low risk malaria infection ; CTX may different impact malaria transmission either holo hyperendemic . Today , WHO recommend daily CTX addition ARVs , prevent opportunistic infection HIV+ , regardless background prevalence CTX microbial resistance . Concurrent administration SP CTX associate increase incidence severe adverse reaction HIV+ patient . Therefore , WHO promote CTX prophylaxis alternative SP IPT immuno-compromised ( CD4 &lt; 350/µl ) pregnant woman . Unfortunately , insufficient information effectiveness daily CTX prevent malaria infection ( placental parasitaemia ) consequence ( maternal anaemia low birth weight ) pregnancy : , presently , SP antimalarial treatment data efficacy safety IPT available , WHO recommend least 2 dos SP give first trimester . With documented increase SP resistance newer antimalarial still study safety efficacy pregnancy , CTX could alternative SP reduce malaria malaria related morbidity mortality pregnancy . The focus study malaria relate outcome pregnancy : target HIV negative HIV positive pregnant woman , assume CTX inferior SP reduce placental parasitaemia . Such information urgently need order issue update , effective guideline intermittent preventive treatment pregnant woman . An open label clinical trial best design ass research question consequence offspring , HIV negative pregnant woman HIV positive pregnant woman CD4 count ≥350/µl . The parallel design choose evaluate group separately , HIV might interact CTX efficacy . Offsets efficacy base literature review .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Confirmed pregnancy ( palpable fundus and/ positive pregnancy test ) Gestational age 16 28 week Hb &gt; 7 g/dl , Hemocue No symptoms consistent malaria Residence within health facility catchment 's area Willingness deliver health facility Willingness adhere requirement study ( include HIV1 voluntary counsel test ) Ability provide write informed consent . If woman minor age/not emancipate , consent must give parent legal guardian accord national law ( however , case , also minor woman sign consent form , document freely give assent take part study ) . History allergy study drug , previous history allergy sulpha drug History presence major illness likely influence pregnancy outcome include diabetes mellitus , severe renal heart disease , active tuberculosis Any significant illness time screen require hospitalization Intent move study 's catchment area delivery deliver relative 's home catchment 's area ; Prior enrolment study concurrent enrolment another study Severe anaemia ( Hb &lt; 7 g/dl ) Previous history unfavourable pregnancy outcome : preeclampsia , caesarean section , stillbirth . Eligible HIVpositive woman , follow National guideline , put CTX prophylaxis ( e.g . CD4 count &lt; 350/µl ) already CTX and/or ARV treatment exclude RCT include prospective observational cohort receive 2 tablet CTX daily</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Prevention</keyword>
	<keyword>HIV</keyword>
	<keyword>Sub-Sahara Africa</keyword>
</DOC>